profit from every TRY 100 of sales.
TRY 0TRY 100
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.
TRY 51.50+4.38% today
-38.0% since Dec 17, 25
1-year low TRY 42.701-year high TRY 131.30
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay TRY 16.90 for every TRY 1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. vs. similar companies
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from TRY 100 of sales | Sales growth a year | Price per TRY 1 of profit |
|---|---|---|---|
| EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. | 16.9× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.'s last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 16.9×
- –
- –
- 0.9×
- 3.6×
- 31.7×
- –
- 3.2%
- 5.9%
- –
Profitability
- 33.4%
- -9.3%
- 21.2%
- –
- 4.5%
- 6.0%
- –
- –
- –
- –
Growth
- +41.7%
- −11.2%
- –
- –
- +0.0%
Financial health
- -0.3×
- 0.05
- –
- 4.4×
- 2.01
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 47%of 948
Bottom 16%of 871
Top 23%of 560
Top 14%of 868
Top 34%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
80Pass
Philip Fisher
48No pass
Peter Lynch
54No pass
Joel Greenblatt
33No pass
Charlie Munger
42No pass
Terry Smith
32No pass
Questions about EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.
Is EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. a good stock to buy?
A strong, very profitable business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. AI analysis
What does EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. do?
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses in Turkey and internationally. It is in Drug Manufacturers - Specialty & Generic.
Is EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. stock halal?
Yes. EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
Who are EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.'s competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.'s.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.